Insulet Co. (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Insulet Co. (NASDAQ:PODD) have been assigned an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $225.29.

A number of brokerages recently issued reports on PODD. Canaccord Genuity Group reaffirmed a “buy” rating and set a $234.00 target price on shares of Insulet in a research report on Tuesday, July 23rd. Redburn Atlantic initiated coverage on shares of Insulet in a report on Thursday, May 30th. They issued a “buy” rating and a $235.00 price target on the stock. OTR Global reissued a “mixed” rating on shares of Insulet in a report on Monday, June 10th. UBS Group boosted their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Finally, Barclays boosted their price target on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th.

Institutional Investors Weigh In On Insulet

A number of hedge funds have recently made changes to their positions in PODD. Sunbelt Securities Inc. bought a new stake in Insulet during the 1st quarter worth about $29,000. International Assets Investment Management LLC bought a new stake in Insulet during the 2nd quarter worth about $32,000. Benjamin F. Edwards & Company Inc. bought a new stake in Insulet during the 4th quarter worth about $34,000. UMB Bank n.a. grew its holdings in Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares during the last quarter. Finally, Jones Financial Companies Lllp bought a new stake in Insulet during the 4th quarter worth about $40,000.

Insulet Price Performance

Shares of Insulet stock opened at $233.89 on Tuesday. The firm has a fifty day simple moving average of $199.93 and a 200-day simple moving average of $186.51. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. Insulet has a 1-year low of $125.82 and a 1-year high of $236.62. The stock has a market capitalization of $16.40 billion, a price-to-earnings ratio of 70.88, a PEG ratio of 4.31 and a beta of 1.21.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. During the same period last year, the firm posted $0.38 EPS. The company’s revenue was up 23.2% compared to the same quarter last year. On average, sell-side analysts expect that Insulet will post 3.04 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.